Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy

Breast cancer, a highly heterogeneous malignancy and a leading cause of cancer-related mortality among women worldwide, is profoundly shaped in its initiation, progression, and therapeutic response by the tumor immune microenvironment (TIME). This review consolidates recent advances in deciphering the cellular, molecular, and metabolic complexity of breast cancer TIME and highlights mechanisms of immune suppression that impede durable treatment efficacy. We critically appraise current and emerging immunotherapeutic approaches, with a focus on strategies that aim to transform immunologically "cold" tumors into "hot," immune-responsive phenotypes. Novel directions, including metabolic modulation, stromal reprogramming, and precision combination therapies, are discussed in the context of overcoming primary and acquired resistance. We highlight emerging biomarker strategies that integrate spatial transcriptomics to map immune exclusion zones, along with liquid biopsy monitoring of exosomal PD-L1 and circulating tumor DNA, to enable real-time adaptation of combination immunotherapy regimens.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-02-13
DOI
https://doi.org/10.3389/fimmu.2026.1760782
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy

Yifan Wang, Ying Liu, J. Zhao, Hooi Tin Ong et al.
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
article

Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy

Yifan Wang, Ying Liu, J. Zhao, Hooi Tin Ong, Yang Zhao, Chen Zhao, Chang Ma, Hoon Koon Teoh
article en

Abstract

Breast cancer, a highly heterogeneous malignancy and a leading cause of cancer-related mortality among women worldwide, is profoundly shaped in its initiation, progression, and therapeutic response by the tumor immune microenvironment (TIME). This review consolidates recent advances in deciphering the cellular, molecular, and metabolic complexity of breast cancer TIME and highlights mechanisms of immune suppression that impede durable treatment efficacy. We critically appraise current and emerging immunotherapeutic approaches, with a focus on strategies that aim to transform immunologically "cold" tumors into "hot," immune-responsive phenotypes. Novel directions, including metabolic modulation, stromal reprogramming, and precision combination therapies, are discussed in the context of overcoming primary and acquired resistance. We highlight emerging biomarker strategies that integrate spatial transcriptomics to map immune exclusion zones, along with liquid biopsy monitoring of exosomal PD-L1 and circulating tumor DNA, to enable real-time adaptation of combination immunotherapy regimens.

Frontiers in ImmunologyVol. 17
People's Liberation Army 401 Hospital (CN), Jilin Medical University (CN), Universiti Tunku Abdul Rahman (MY)
Universiti Tunku Abdul Rahman, People's Government of Jilin Province
Good health and well-being
Openalex Percentile: Top 56%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.